AI-assisted clinical decision support across the cancer treatment pathway

From workup and investigations to MDT decisions, treatment and survivorship, OncoSync keeps the whole team aligned, so no decision or record is lost and no patient slips through.

Request demo Explore the platform

The patient journey

Eleven stages. One continuous record.

STAGE 01

Workup

The full clinical story — assembled on day one.

Identity, ABHA and insurance captured in one pass

History, symptoms and general examination on the same record

Clinical staging closes the workup before investigations open

Try it: type into any field, pick a blood group, then Save & Proceed

Sunita Deshmukh#PAT001Tumour Board: Breast MDT GroupAudit TrailClinical Journey9+PRDr. Priya Raghavan

WORKUP Collapse all

Patient Details

Clinical Workup · Full Assessment

STAGE 01

Salutation *Patient Name *Date of BirthAgeyrsGenderBlood GroupABHA IDAadhaar IDMedical Insurance IDInsurance CompanyEmergency Contact NameRelationshipPhone NumberAddress *

STAGE 02

Investigations

Order it. Upload it. Discuss it. No phone tag.

One request assembled across imaging, blood, pathology and genetics

A scan joins the request only once its site has been chosen

Blood panels show how many of their markers are already ordered

Try it: pick MRI and choose a site, or open the Blood tab

Sunita Deshmukh#PAT001Tumour Board: Breast MDT GroupAudit TrailClinical Journey9+PRDr. Priya Raghavan

INVESTIGATIONS Collapse all

Investigations

Request Investigation

STAGE 02

Template:Select template

Search for any test, scan, or marker…

Non-vascular interventionReport Requests24

STAGE 03

Provisional treatment plan

Walk into MDT already ahead.

Sequencing drafted before MDT — neoadjuvant or adjuvant

Reason for submission tagged: radiology, pathology, planning

Saved and sent to MDT from the same screen

Try it: tick a reason for MDT, write the plan, then Save

Sunita Deshmukh#PAT001Tumour Board: Breast MDT GroupAudit TrailClinical Journey9+PRDr. Priya Raghavan

TREATMENT PLAN Collapse all

Provisional Treatment Plan

Provisional planning before MDT

STAGE 03

DiagnosisFinal diagnosis · entered at Workup › Diagnosis on 08 Sep 2026 by Dr. Priya Raghavan — edit it there, not hereFROM WORKUP

Invasive ductal carcinoma (NST), right breast upper outer quadrant — Nottingham Grade 2, ER positive 90%, PR positive 70%, HER2 negative (1+), Ki-67 25%. Luminal B.

Provisional Treatment PlanProvisional planning before MDTTreatment Plan

Neoadjuvant chemotherapy to downstage the primary and read the in-vivo response, then breast-conserving surgery with targeted axillary surgery. Baseline echocardiogram for LVEF before the anthracycline. Adjuvant whole-breast radiotherapy, then five years of an aromatase inhibitor — she is postmenopausal. Genetic counselling referral already placed on the maternal family history. Glycaemic control to be optimised with the physician before cycle 1 (HbA1c 7.4%).

Your queries to MDT / Reason for submitting to MDT (Multi-select)

Other

Neoadjuvant versus upfront surgery for a 32 mm ER-high tumour, and axillary management if the marked node is positive after chemotherapy.

Save

STAGE 04

MDT presentation & decision

Where tumour board members review, discuss, and decide.

The query raised at submission is what the panel answers

Discussion happens live, on the record, against the case

Recommendation signed in the meeting

Try it: switch to Discussion notes and post a message, or read the panel's opinions

Sunita Deshmukh#PAT001Tumour Board: Breast MDT GroupAudit TrailClinical Journey9+PRDr. Priya Raghavan

MDT Collapse all

MDT Discussions

1 open · 2 closed · MDT · Multidisciplinary Team

STAGE 04

5/6Updated just now

Dr. Priya Raghavan LEADYOUSpecialistSubmitted

Neoadjuvant chemotherapy, then breast-conserving surgery. Clip the involved node before cycle 1 and plan targeted axillary dissection.

Dr. Arjun MehtaSpecialistSubmitted

Chemotherapy first is justified by grade, Ki-67 and nodal status. Baseline echocardiogram before the anthracycline; optimise glycaemic control first.

Dr. Meera ShahSpecialistSubmitted

Core is sufficient — no further tissue needed before treatment. I will report the clipped node separately.

Dr. Karan MalhotraSpecialistSubmitted

Will clip and mark the larger axillary node under ultrasound before cycle 1.

Dr. Lakshmi IyerSpecialistSubmitted

Whole-breast radiotherapy after conservation. Nodal fields to be revisited on the post-chemotherapy axillary result.

Sneha JoshiMDT CoordinatorPending

Awaiting recommendation

STAGE 05

Planning & treatment

The MDT decision becomes a step-by-step treatment plan.

Stage, receptors and risk carried over from Workup, not retyped

Neoadjuvant, surgical and adjuvant steps laid out in the order they happen

Regimens picked from the library, or built with Create Regimen

Try it: open a step of the neoadjuvant plan, or press Create Regimen

Sunita Deshmukh#PAT001Tumour Board: Breast MDT GroupAudit TrailClinical Journey9+PRDr. Priya Raghavan

PLANNING & TREATMENT Collapse all

Medical Oncology Planning

Planning & Treatment

STAGE 05

Regimen Library

Chemotherapy regimens — all shown initially; apply filters to search

Grade 2, Ki-67 25% and node-positive disease — chemotherapy is earned, and giving it first downstages a 32 mm tumour for breast conservation.

STAGE 06

Surgery

Procedure and margins fold straight back into the case.

Treatment areas picked first — the procedure list rebuilds to match

Each operated site carries its own procedures and planned date

Decisions raised here come back here once the board closes them

Try it: tick a treatment area, open a site, then expand a procedure

Sunita Deshmukh#PAT001Tumour Board: Breast MDT GroupAudit TrailClinical Journey9+PRDr. Priya Raghavan

PLANNING & TREATMENT Collapse all

Surgical Planning

Planning & Treatment

STAGE 06

Treatment to the:

QUICK ADD PROCEDURESearch procedures (e.g. BCS, SLNB, MRM, Mastectomy…)

BREAST PROCEDURES

Please enter detailed description here

AXILLA PROCEDURES

Update & Proceed

MDT DECISION · R3Closed 22 Sep 2026

Surgical planning — MDT input requested

Raised from this section. Breast-conserving surgery on the right once the taxane is finished; restage with ultrasound and MRI before a date is committed.

Dr. Priya Raghavan · 6 of 6 opinions recorded · closed 22 Sep 2026

MDT DECISION · R2Closed 18 Sep 2026

Axillary management — MDT input requested

Raised from this section. Targeted axillary dissection after systemic therapy; proceed to full ALND only if the marked node is positive.

Dr. Priya Raghavan · 5 of 6 opinions recorded · closed 18 Sep 2026

STAGE 07

Chemotherapy

Cycle by cycle, with every dose change on the record.

Regimen chosen from the library, filtered to the diagnosis

Dose modifications recorded on the cycle they start

Each cycle cleared before it runs

Try it: set the ECOG score, tick a symptom, then open Cycle Clearance Decision

AC → Paclitaxel

Sunita DeshmukhID: PAT001Phase / CycleCycle 1

CLINICAL ASSESSMENTMark as completed

PATIENT MEASUREMENTS

Weight68kgHeight5.18ft

BSA = 1.73 m² (Mosteller)

ECOG PERFORMANCE STATUS

1 — Restricted in strenuous activity; ambulatory and able to carry out light work

SYMPTOM CHECKLIST Trends

Mild symptoms

STAGE 08

Radiation

Fractions and dose constraints tracked against the plan.

Fraction delivery reconciled daily

Dose constraints flagged before breach

Toxicity graded against CTCAE

Try it: step through the planning workflow rail, set positioning, then Save Plan

Sunita DeshmukhMRN PAT001 · FEMALE · 52y | eRTR

Fraction delivery calendarClick a day for delivery detail · click a week to open the on-treatment assessment

CompletedMissed / gapCompensationScheduledOmitted

MONTUEWEDTHUFRISAT

COMPLIANCE DASHBOARD

Fx completed1 / 25Dose delivered5%OTT in targetYesInterruptions0CompensationNoOTT delta0 d

Dose delivered · 1 of 25 fractions delivered · 24 still to goTreatment adherence0 interruptions · +0 d OTT slipGood

PLAN VERSIONS

v1Original approved planACTIVE50.05 Gy / 25 Fx · 2.67 Gy/fx × 15 + boost 1 Gy/fx × 10 · Fx 1 → ongoingDose/Technique re-entry

Treatment completionIN PROGRESS

Treatment completion summary

RT started15 Apr 2027RT completed—Total dose2.67 GyFx delivered1 / 25Fx missed0OTT1 dBoost10 Gy / 10 FxHighest toxicity—

Completion status

Electronic sign-off chainDosimetristsignedRT TechnologistsignedMedical PhysicistsignedRadiation oncologistsignedCompletedsigned

1/25 fractions · IN PROGRESS Completion report

STAGE 09

Follow-up & survivorship

Treatment ends. The care doesn’t.

Adjuvant letrozole tracked with bone-density monitoring

Surveillance mammography generated from protocol

Outcomes reported back to the panel that decided

Try it: read the BCFRS domain scores, or switch section in the rail on the left

Planning & TreatmentFollow-up and SurveillanceSunita Deshmukh

Longitudinal follow-up timeline

Diagnosis08 Sep 2026

ChemotherapyAC ×4 (q2w) → Paclitaxel ×12 (weekly)

Surgery05 Mar 2027 · BCS + TAD

Radiotherapy50.05 Gy / 25 Fx · Apr–May 2027

Endocrine therapyLetrozole · from May 2027

Current follow-up10 Jun 2027

Next visit10 Sep 2027

Three sibling instruments, one visual language.

BCFRS measures how well recovery has gone, BRAT measures what rehab is still needed, and BCSA is the periodic comprehensive check-in that drives follow-up.

BCFRS DOMAIN PROFILEFrom the most recently saved BCFRS assessmentPhysical21/25Upper Limb10/20Pain10/15ADL13/15Psych10/10Lifestyle10/10Work5/5

Breast Cancer Functional Recovery Score (BCFRS)How well has the patient recovered overall?Recorded 10 Jun 2027

Physical Function21 / 25

Shoulder Flexion

>170°

Shoulder Abduction

>170°

Internal Rotation

Moderate restriction

External Rotation

Moderate restriction

Grip Strength (vs. contralateral side)

≥95%

Upper Limb Function10 / 20

Arm Swelling

Marked

Lymphedema Stage (ISL)

Stage II

Arm Use (lifting / combing / dressing / reaching)

Moderate difficulty

Shoulder Stiffness

Severe

Pain & Symptoms10 / 15

Average Pain Score (NRS)

3–4

Neuropathic Pain

Occasional

Fatigue

Moderate

Activities of Daily Living13 / 15

Independent Tasks (dress / bathe / cook / carry groceries)

Completely independent

Household Activities

Completely independent

Exercise Capacity

60–89 min/week

Psychosocial Recovery10 / 10

Emotional Well-being

Very good

Body Image

Very satisfied

Lifestyle & Wellness10 / 10

Sleep Quality

Excellent

Healthy Lifestyle Adherence

Excellent

Return to Normal Life5 / 5

Return to Work / Routine

Returned completely

STAGE 10

Palliative & supportive care

Symptom control and goals of care, screened and routed like everything else.

Referral level scored from symptom burden, not left to judgement alone

Critical triggers force escalation regardless of the calculated score

Disease setting, intent and trajectory captured alongside it

Try it: tick a critical trigger, change the treatment intent, then Reset

Palliative & Supportive CareScreening, referral and symptom-directed care · clinician-ledVisit 2● Level 0 (routine)Expand all

Dashboard & Referral EligibilityScreen, score and route palliative-care need — the clinician decides the level.

Referral level

Level 0

Routine

Symptom burden

Low

Pain 2/10 · arthralgia

ECOG

Ambulatory · light work

Reassessment due

10 Sep 2027

With the next follow-up visit

Critical override triggers

Any one of these forces level 3 or 4 regardless of the calculated score

Other / additional

Saved

Eligibility input domainsJudgment-based fields are manual entry only — never inferred from another module2/8

A · Disease status

Setting, intent and trajectory of the cancer itself

Disease setting

Treatment intent

Disease trajectory

STAGE 11

Clinical trials

Matched against open protocols the moment the diagnosis is confirmed.

Eligibility screened against demographics, stage and biomarkers already on the case

Match strength shown with the data gaps behind it, not just a yes or no

Recommended to MDT straight from the match

Try it: filter the matches, then Recommend to MDT from any trial card

Clinical Trial MatchingPrecision research engine · screening & matching

FilterSort

3 matched trials · sorted by best match

moderate

Adjuvant CDK4/6 inhibitor in node-positive HR+/HER2− early breast cancerPhase II

CTRI/2025/02/069533 · adjuvant

Moderate match · Partial fit — protocol wants ≥4 positive nodes, or 1–3 with grade 3 or tumour ≥5 cm (1/4 nodes, grade 2).

RecruitingCTRIpharma

moderate

Extended adjuvant endocrine therapy ± CDK4/6 inhibitor in HR+ breast cancerPhase III

CTRI/2024/11/058991 · adjuvant

Moderate match · Fits — HR-positive, postmenopausal, already on an adjuvant aromatase inhibitor.

RecruitingClinicalTrials.govacademicHigh-quality monitoring

low

Maintenance olaparib in BRCA-mutated HER2-negative high-risk breast cancerPhase III

CTRI/2025/01/061204 · adjuvant-maintenance

Low match · Fits clinically — residual disease and node-positive; germline BRCA1/2 result still pending.

RecruitingCTRIacademicFree study drug

Explore the platform

Go deeper where it matters to you

Each area has its own walkthrough — start wherever your review begins.

Cancer Care

Every module the panel touches — workflow, timeline, trials, analytics — on one data model.

Clinical Intelligence Network

Hubs, district units, radiotherapy centres and labs working the same case with scoped access.

Security & Compliance

Guideline references on the recommendation, access scoped to the case, and an audit trail behind it.

Account types

Choose your account type

Each option unlocks a platform account type and the MDT / CIN features that type can use.

Specialist

Individual specialist account for CIN & MDT practice

Clinical Intelligence Network (CIN) practice

Consultations, campaigns & earnings

Join hospital MDT teams when invited

Specialty-based clinical workspace

Patient cases, tumour boards & MDT discussions

Select

Clinical Group

Clinic admin account for small MDT teams

Invite MDT Coordinators & Specialists

Patients, tumour boards & case discussions

Diagnostic queries & treatment planning

Recruit CIN specialists via campaigns

Hospital permission matrix for team access

Select

Hospital

Hospital admin account for full MDT operations

Full MDT team: Coordinators, Admins & Specialists

Surgical, systemic, radiation & follow-up planning

Approvals, submissions & lead-specialist workflows

CIN recruitment, hiring & work history

Branch-ready staff & RBAC administration

Select

Enterprise

Enterprise admin account for multi-hospital networks

Multi-hospital & branch management

Assign MDT Admins per hospital branch

Enterprise-wide dashboard & overview

Scale Coordinators & Specialists across sites

Full MDT + CIN recruitment across the network

Select

Already have an account? Sign in here